Indeed, several therapeutic classes—including renin–angiotensin–aldosterone system inhibitors (RAASis), non-steroidal mineralocorticoid receptor antagonists (ns-MRAs), sodium-glucose cotransporter-2 inhibitors (SGLT2is), and glucagone-like-peptide-1 receptor agonists (GLP-1 RAs)—have demonstrated benefits in both HF and CKD, underscoring the overlap in their pathogenesis and treatment strategies [3,4,5,6]. This evidence concerns the gene REN and hydrops fetalis.